Treatment of viral conjunctivitis with antiviral drugs.


:Viral conjunctivitis is one of the most common disorders observed in ophthalmic emergency departments, yet no established treatment exists. Lately, antiviral medications have been introduced into clinical practice; however, a systematic review focusing on their use and effectiveness in the treatment of viral conjunctivitis has not been previously reported. We systemically reviewed the literature to identify studies where antiviral drugs were used to treat viral conjunctivitis. Currently, aciclovir, trifluridine and valaciclovir are commonly used as antiviral agents to treat herpesvirus infections. Cidofovir has been used successfully to treat some cases of adenoviral conjunctivitis, although toxicity has also been reported. The use of other medications, such as idoxuridine, has been minimized in clinical practice due to their high toxicity. Interestingly, most of the antiviral drugs developed are used to treat herpesvirus infections, while less progress has been made in the field of adenoviral infections. For other viral causes of conjunctivitis, no effective remedy is currently available, and treatment focuses on the relief of symptoms. Caution should be exercised when coadministering other pharmacological agents, such as corticosteroids, because of emerging adverse effects.






Skevaki CL,Galani IE,Pararas MV,Giannopoulou KP,Tsakris A




Has Abstract


2011-02-12 00:00:00
















  • Endothelial function. General considerations.

    abstract::The endothelium is involved in both the physiological regulation of vascular tone and the structural transformation of the vessel under pathological conditions. Under physiological conditions, endothelial cells continuously secrete nitric oxide (NO), which relaxes smooth muscle cells and ensures vessel patency. Damage...


    pub_type: 杂志文章,评审


    authors: Haller H

    更新日期:1997-01-01 00:00:00

  • Clinical efficacy of ofloxacin in lower respiratory tract infections. A multicentre study.

    abstract::A multicentre clinical trial was carried out to determine the activity and tolerability of ofloxacin in the treatment of lower respiratory tract infections. 667 patients were randomly allocated to 1 of 3 different twice daily dosage regimens: 400 mg (245 patients), 600 mg (211) or 800 mg (211). The mean duration of tr...


    pub_type: 临床试验,杂志文章,随机对照试验


    authors: Grassi C,Gialdroni Grassi G,Mangiarotti P

    更新日期:1987-01-01 00:00:00

  • Oxantel-pyrantel in various regimens for the treatment of soil transmitted helminthiasis in rural and urban communities.

    abstract::204 individuals from a rural community were given a single dose of oxantel-pyrantel at 15mg/kg bodyweight and if still infected, 20mg/kg bodyweight, with cure rates of 100%, 53% and 71% for ascariasis, trichuriasis and hookworm infection, respectively. From an urban community, 124 patients were given the same drug eit...


    pub_type: 临床试验,杂志文章


    authors: Cabrera BD,Sy FS

    更新日期:1978-01-01 00:00:00

  • Airway and lung remodelling in chronic pulmonary obstructive disease: a role for muscarinic receptor antagonists?

    abstract::Lung tissue remodelling in chronic inflammatory lung diseases has long been regarded as a follow-up event to inflammation. Recent studies have indicated that, although airway and lung tissue remodelling is often independent of inflammation, it precedes or causes inflammation. None of the available therapies has a sign...


    pub_type: 杂志文章,评审


    authors: Roth M

    更新日期:2015-01-01 00:00:00

  • Danoprevir: First Global Approval.

    abstract::Ascletis has developed danoprevir (Ganovo®), an orally-administered hepatitis C virus NS3 protease inhibitor, as a treatment for hepatitis C. Based on positive results in phase II and phase III trials in patients with hepatitis C, danoprevir, in combination with ritonavir, peginterferon alfa and ribavirin was recently...


    pub_type: 杂志文章,评审


    authors: Markham A,Keam SJ

    更新日期:2018-08-01 00:00:00

  • Panic disorder. Pathophysiology and drug treatment.

    abstract::Advances over the past 2 decades in our understanding of the biology of panic disorder have paralleled a remarkable increase in the development of new pharmacological agents with antipanic effects. Although we can not presently use biological tests to help with our choice of therapeutic agent for individual patients, ...


    pub_type: 杂志文章,评审


    authors: Johnson MR,Lydiard RB,Ballenger JC

    更新日期:1995-03-01 00:00:00

  • Statins and menopause.

    abstract::During the reproductive period, women generally have lower low-density lipoprotein (LDL) cholesterol and higher high-density lipoprotein cholesterol than age- and diet-matched men. However, these possibly antiatherogenic characteristics of lipoproteins are changed to a potentially atherogenic profile after menopause. ...


    pub_type: 杂志文章,评审


    authors: Moghadasian MH

    更新日期:2002-01-01 00:00:00

  • Antidepressants for the treatment of insomnia : a suitable approach?

    abstract::The popularity of antidepressants in the treatment of insomnia is not supported by a large amount of convincing data, but rather by opinions and beliefs of the prescribing physicians on the advantages of these agents compared with drugs acting on the benzodiazepine receptor or other drugs used for the treatment of ins...


    pub_type: 杂志文章


    authors: Wiegand MH

    更新日期:2008-01-01 00:00:00

  • A clinical assessment of the potential for pharmacological interaction between nimesulide and digoxin in patients with heart failure.

    abstract::The potential interaction between nimesulide, a nonsteroidal anti-inflammatory drug, and digoxin was studied in 9 patients [6 males, 3 females; mean age 67 (range 57 to 70) years] with mild heart failure. All patients were receiving maintenance therapy with digoxin (0.25 mg/day, orally) and were treated with oral nime...


    pub_type: 杂志文章


    authors: Baggio E,Maraffi F,Montalto C,Nava ML,Torti L,Casciarri I

    更新日期:1993-01-01 00:00:00

  • Pharmacologic management of advanced cervical cancer: antiangiogenesis therapy and immunotherapeutic considerations.

    abstract::As a consequence of disparities in access to and utilization of preventative healthcare, the incidence and death rates from cervical cancer remain substantial in the face of indisputable evidence that screening saves lives. While disparities persist, there will be an urgent need for research into the treatment of adva...


    pub_type: 杂志文章,评审


    authors: Longoria TC,Tewari KS

    更新日期:2015-11-01 00:00:00

  • Clinical efficacy and tolerability of cefixime in the treatment of acute sinusitis.

    abstract::In a noncomparative trial, 73 adults with acute sinusitis confirmed by x-ray received cefixime 400mg once daily for approximately 10 days. At the end of treatment, 60 patients (82%) were cured, 2 (2.7%) had improved and 7 (9.6%) had failed therapy; 4 patients were not evaluable. No relapses were observed at follow-up....


    pub_type: 临床试验,杂志文章


    authors: Gehanno P,Boucot I,Berche P,Uhlrich J

    更新日期:1991-01-01 00:00:00

  • Immune Checkpoint Blockade in Oncogene-Driven Non-Small-Cell Lung Cancer.

    abstract::Patients with oncogene-driven lung cancer have limited therapeutic options after progressing on their targeted tyrosine kinase inhibitor (TKI) therapy. Given the growing role of immune checkpoint inhibitor (ICI) therapy in the treatment of lung cancer, oncogene-driven cancer has warranted further evaluation regarding ...


    pub_type: 杂志文章,评审


    authors: Somasundaram A,Socinski MA,Villaruz LC

    更新日期:2020-06-01 00:00:00

  • Losartan/Hydrochlorothiazide: a review of its use in the treatment of hypertension and for stroke risk reduction in patients with hypertension and left ventricular hypertrophy.

    abstract::Losartan/hydrochlorothiazide (HCTZ) [Hyzaar(R)] is a fixed-dose combination of the angiotensin II receptor antagonist (angiotensin receptor blocker [ARB]) losartan and the thiazide diuretic HCTZ. It is indicated for the treatment of hypertension (including as initial therapy in severe hypertension) and for stroke risk...


    pub_type: 杂志文章,评审


    authors: Keating GM

    更新日期:2009-06-18 00:00:00

  • Orlistat: in the prevention and treatment of type 2 diabetes mellitus.

    abstract::Orlistat is a nonsystemically acting gastric and pancreatic lipase inhibitor that limits the absorption of dietary fat. A retrospective pooled analysis of three 2-year, double-blind, randomised, placebo-controlled trials involving patients with obesity revealed that orlistat recipients were more likely to experience a...


    pub_type: 杂志文章,评审


    authors: Keating GM,Jarvis B

    更新日期:2001-01-01 00:00:00

  • Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s. Achievements and future developments.

    abstract::Non-insulin-dependent diabetes mellitus (NIDDM, type 2 diabetes) is a heterogeneous disease resulting from a dynamic interaction between defects in insulin secretion and insulin action. There are various pharmacological approaches to improving glucose homeostasis, but those currently used in clinical practice either d...


    pub_type: 杂志文章,评审


    authors: Scheen AJ

    更新日期:1997-09-01 00:00:00

  • Acitretin. A review of its pharmacology and therapeutic use.

    abstract::Acitretin (etretin), a second generation monoaromatic retinoid for use in the treatment of severe psoriasis and other dermatoses, is the major active metabolite of etretinate and possesses a similar therapeutic index; i.e. a similar ratio of clinical efficacy to adverse effects. When used alone at a maintenance dosage...


    pub_type: 杂志文章,评审


    authors: Pilkington T,Brogden RN

    更新日期:1992-04-01 00:00:00

  • An overview of the long-term safety experience of nabumetone.

    abstract::Safety data have been gathered in US clinical trials of nabumetone on 1912 patients from August 1981 to May 1988. Dosing in the double-blind trials was 100 mg at bedtime, but in open-label trials patients could increase the dosage of nabumetone to 1500 or 2000 mg if required. Adverse experiences reported in the double...


    pub_type: 临床试验,杂志文章


    authors: Willkens RF

    更新日期:1990-01-01 00:00:00

  • Etanercept: a review of its use in autoimmune inflammatory diseases.

    abstract::With its approval more than 15 years ago, subcutaneous etanercept (Enbrel(®)) was the first biological disease-modifying antirheumatic drug (bDMARD) and the first tumour necrosis factor inhibitor to be approved for use in rheumatic diseases. Etanercept remains an important cost-effective treatment option in adult pati...


    pub_type: 杂志文章,评审


    authors: Scott LJ

    更新日期:2014-08-01 00:00:00

  • The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day.

    abstract::Our knowledge of the mechanisms of platelet-mediated thrombosis has increased dramatically over the last 40 years. This increased understanding has identified treatment strategies for acute coronary syndromes (ACS) by targeting key mediators of platelet activation and aggregation processes. Aspirin (acetylsalicylic ac...


    pub_type: 杂志文章,评审


    authors: Angiolillo DJ

    更新日期:2012-11-12 00:00:00

  • Damoctocog Alfa Pegol: A Review in Haemophilia A.

    abstract::Damoctocog alfa pegol (Jivi®) is approved in the USA, EU, Japan and Canada for the treatment and prophylaxis of previously treated patients aged ≥ 12 years with haemophilia A. Formulated with a 60 kDa polyethylene glycol (PEG) moiety, damoctocog alfa pegol is an intravenously (IV) administered recombinant factor VIII ...


    pub_type: 杂志文章,评审


    authors: Paik J,Deeks ED

    更新日期:2019-07-01 00:00:00

  • Optimal therapeutic strategies for resectable oesophageal or oesophagogastric junction cancer.

    abstract::Oesophageal cancer is the eighth most common cancer diagnosed worldwide, with almost half a million new cases diagnosed each year. Despite improvements in surgical and radiotherapy techniques and refinements of chemotherapeutic regimens, long-term survival, even from localized oesophageal cancer, remains poor. Surgica...


    pub_type: 杂志文章,评审


    authors: Bystricky B,Okines AF,Cunningham D

    更新日期:2011-03-26 00:00:00

  • Pinacidil with and without hydrochlorothiazide. Dose-response relationships from results of a 4 x 3 factorial design study.

    abstract::Utilising a modified fixed-dose, 4 x 3 factorial design, the antihypertensive effects of all combinations of 4 doses of pinacidil (0, 12.5, 25 and 37.5 mg bid) with 3 doses of hydrochlorothiazide (0, 12.5 and 25 mg bid) were studied in patients with supine diastolic blood pressure of 95 to 110mm Hg. The decreases in s...


    pub_type: 临床试验,杂志文章,随机对照试验


    authors: Goldberg MR,Offen WW

    更新日期:1988-01-01 00:00:00

  • Emicizumab: A Review in Haemophilia A.

    abstract::Emicizumab (Hemlibra®), a recombinant, humanized, bispecific monoclonal antibody, restores the function of missing activated factor VIII (FVIII) by bridging FIXa and FX to facilitate effective haemostasis in patients with haemophilia A. Subcutaneous emicizumab is approved in several countries, including in the USA and...


    pub_type: 杂志文章,评审


    authors: Blair HA

    更新日期:2019-10-01 00:00:00

  • Diuretic-induced magnesium losses.

    abstract::Long term administration of common loop or distal tubular diuretics may cause somatic magnesium depletion. The resultant deficiency of Mg++ destabilises the myocardium electrically and is a principal cause of cardiac arrhythmias ascribed to diuretics. The adverse effects of diuretics caused by Mg++ depletion can be av...


    pub_type: 杂志文章


    authors: Leary WP,Reyes AJ

    更新日期:1984-10-01 00:00:00

  • Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification.

    abstract::Acamprosate (calcium acetylhomotaurinate), a synthetic compound with a similar chemical structure to that of gamma-aminobutyric acid, is thought to act via several mechanisms affecting multiple neurotransmitter systems; inhibition of neuronal hyperexcitability by antagonism of excitatory amino acid activity and reduct...


    pub_type: 杂志文章,评审


    authors: Wilde MI,Wagstaff AJ

    更新日期:1997-06-01 00:00:00

  • Therapeutic experience with temocillin in peritonitis.

    abstract::The therapeutic efficacy of the new beta-lactam antibiotic, temocillin, was studied in 30 critically ill patients with peritonitis, abscesses, bronchopneumonia, and serious soft tissue infections. Patients were treated with temocillin Ig intravenously twice daily. The isolated pathogens comprised mainly Escherichia co...


    pub_type: 杂志文章


    authors: Pfeiffer M,Fock RR

    更新日期:1985-01-01 00:00:00

  • Coming to terms with nonsteroidal anti-inflammatory drug gastropathy.

    abstract::Despite well known complications, oral nonsteroidal anti-inflammatory drugs (NSAIDs) remain the most commonly prescribed medications in the US for musculoskeletal disorders such as osteoarthritis. Although there has been a recent focus on the cardiovascular and renal complications associated with these agents, NSAID g...


    pub_type: 杂志文章,评审


    authors: Roth SH

    更新日期:2012-05-07 00:00:00

  • Advanced-stage follicular lymphoma in the rituximab era: when should patients receive anthracycline-based chemotherapy?

    abstract::Follicular lymphoma (FL), the most common subtype of indolent lymphoma, is usually diagnosed at an advanced stage (III-IV), although patients are often asymptomatic. Traditionally, a palliative approach to management has been taken, cycling through watchful waiting, radiotherapy, oral alkylating agents and, eventually...


    pub_type: 杂志文章


    authors: Pettengell R

    更新日期:2009-01-01 00:00:00

  • Microbiological evaluation of cefpodoxime proxetil.

    abstract::Cefpodoxime, the active de-esterified molecule of the orally absorbable cephalosporin cefpodoxime proxetil, inhibits streptococci, Neisseria spp., and most Enterobacteriaceae, with MIC50 and/or MIC90 values of less than or equal to 2 mg/L; with regard to the latter family of bacteria, the MIC50 and/or MIC90 values of ...


    pub_type: 杂志文章


    authors: Wiedemann B,Luhmer E,Zühlsdorf MT

    更新日期:1991-01-01 00:00:00

  • Bisoprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris.

    abstract::Bisoprolol is a beta 1-adrenoceptor antagonist with no partial agonist (intrinsic sympathomimetic) activity or membrane stabilising (local anaesthetic) activity. The oral bioavailability of bisoprolol is high (90%) and the drug has a long elimination half-life which allows once-daily administration; in addition, it is...


    pub_type: 杂志文章,评审


    authors: Lancaster SG,Sorkin EM

    更新日期:1988-09-01 00:00:00